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Abstract 
Rheumatoid Arthritis (RA) and Crohn’s Disease (CD) are both chronic inflammatory diseases 
that share developmental and treatment similarities. RA’s symptoms include swelling, stiffness, 
and pain in synovial joints, corresponding with bone and cartilage destruction. CD’s symptoms 
include abdominal pain, bowel obstruction, bloating, diarrhea, and fever. The purpose of this 
literature review was to investigate the links between these two diseases and propose future 
treatment and prevention targets. Current treatment for RA and CD aims to suppress 
inflammation by targeting its mediators. However, this review noted that there should be greater 
focus on resolving inflammation.  Both diseases are characterized by the non-resolution of 
chronic inflammation due to the interplay of specific cytokines (IL-1, IL-6, TNF), which are 
proteins that function in cell to cell communication, and due to the dysbiosis of the oral and gut 
microbiome, which involves a compositional change of residing bacteria. Individuals are 
predisposed to both diseases via heritability and environmental factors, such as smoking. Finally, 
development and severity of both diseases depend on mutations in specific regulatory genes, 
such as STAT4 and PTPN2/22. Targeting the influx of immune cells, stimulating pro-resolving 
mediators such as IL-9 and 10, and restoring eubiosis are possible inflammation-resolving 
mechanisms. There should also be a movement towards prevention rather than disease 
intervention. Prevention tactics may include the promotion of oral and gut health, quitting 
smoking, and screening for genetic susceptibility. 
Keywords: Rheumatoid Arthritis, Crohn’s Disease, dysbiosis, inflammation 
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The Interplay of the Oral-Gut Microbiome with Chronic Inflammation in Rheumatoid Arthritis 
and Crohn’s Disease 
Introduction 
 A malfunctioning immune system is the cornerstone of autoimmune diseases, cancers, 
and chronic inflammatory diseases. The immune system is composed of leukocytes, cytokines, 
chemokines, antimicrobial proteins, and barriers, to help to protect the body against foreign 
invaders. When it malfunctions, local tissue damage and widespread inflammation can result. 
Rheumatoid Arthritis (RA) and Crohn’s Disease (CD) are chronic inflammatory conditions that 
result from inappropriate immune responses against self-antigens and commensal bacteria, 
respectively.  
 RA has become an increasingly prominent extraintestinal manifestation of CD (Yang et 
al., 2018; Georgiadis, Tzambouras, Ioachim, Tsianos, Agnantis, & Drosos, 2003). For example, a 
study in South Korea found that RA was found in 10/1000 CD cases (Yang et al., 2018).  This 
association begs the following question: Are RA and CD merely coexisting diseases for some 
patients or do they share genetic and environmental links that point to similar developments? 
This literature review aims to investigate the treatments, inflammatory, environmental, and 
genetic susceptibility factors shared by RA and CD. This analysis will then be used to propose 
possible treatment and diagnosis options that could target both diseases to prevent or delay 
disease onset.  
Role of Chronic Inflammation in RA and CD Etiology 
RA Overview 
 RA is a T cell mediated autoimmune disorder that affects approximately 1% of the 
world’s population (Cusick, Libbey, & Fujinami, 2012). RA is characterized by inflammation of 
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the synovial membrane surrounding the joints.  RA’s synovial inflammation leads to cartilage 
damage, bone erosion, thickening of the synovial membrane, formation of rheumatoid nodules, 
fatigue, stiffness and swelling of joints (Klareskog, Catrina & Paget, 2009; Chauhan & Al-
Dhahir, 2018). The bone and cartilage damage present in RA patients are due to matrix 
metalloproteinases (MMPs). MMPs, released by macrophages and fibroblasts, work to gradually 
destroy the proteins needed to maintain the extracellular matrix structure. Extra-articular damage 
is also present with RA comorbidities, such as cardiovascular disease, osteoporosis, and 
lymphomas (Klareskog et al., 2009).  A loss of tolerance towards citrullinated proteins is the 
hallmark of RA autoimmunity. The enzyme, peptidylarginine deiminase (PAD), facilitates the 
citrullination of proteins. Citrullinated proteins are presented by MHC Class II, where they are 
eventually recognized by T cells. These T cells proceed to interact with and activate B cells, 
which then produce and release antibodies against citrullinated protein antigens (ACPAs). 
ACPAs can recognize, bind, and neutralize the citrullinated protein antigen. ACPA is used as a 
diagnostic tool and a measure of RA severity, since its serum levels are correlated to the severity 
of RA symptoms (Du Teil Espina, Gabarrini, Harmsen, Westra, Winkelhoff & Van Dijl, 2018). 
CD Overview 
 CD is a type of Inflammatory Bowel Disease (IBD) that involves inflammation of the 
gastrointestinal tract, particularly the distal ileum (Ranasinghe & Hsu, 2018). The chronic 
inflammation associated with CD is responsible for the ulceration of the mucosal layers and 
granuloma formation in the distal small intestine (Boyapati, Satsangi, & Ho, 2015). Chronic 
inflammation develops due to the malfunctioning immune system incorrectly identifying normal 
flora as pathogenic (Margo & Portela, 2010). One of the most widely studied genetic risk factor 
for CD is the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), 
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previously known as CARD15. NOD2 is expressed in immune cells and intestinal epithelial 
cells, termed Paneth cells. These proteins are essential in turning on the Nuclear Factor-Kappa-B 
(NF-kB) pathway. Mutations of the NOD2 gene are found in 40% of Western CD patients and 
disrupt the protein’s ability to recognize foreign microbes (Boyapati et al., 2015). This then 
negatively affects the cell’s ability to process intracellular microbes (Boyapati et al., 2015). This 
malfunctioning immune response is further amplified by a leaky epithelial barrier, non-regulation 
of T cells, increased persistence of Toll-like Receptors (TLRs), and impaired autophagy (Margo 
& Portela, 2010; Baumgart & Sandborn, 2012). The impaired intestinal epithelial barrier is due 
in part to the action of Paneth cells. Paneth cells participate in the immune response by releasing 
antimicrobial granules. In CD, Paneth cells tend to have the 300T autophagy gene variant which 
decreases and disrupts granule release and autophagy (Baumgart & Sandborn, 2012). The 
epithelial layer is further compromised by the leaky tight junctions which allows for the invasion 
of more immune cells. These defective immune responses irritate the intestinal lining and 
mucosal layer and lead to symptoms, such as abdominal pain/tenderness, diarrhea, digestive tract 
irritation, bloating, gas, fever, weight loss, and anemia (NIH, 2017; Ranasinghe & Hsu, 2018). 
Non-resolution of Chronic Inflammation 
 RA and CD are chronic inflammatory diseases, mediated mainly by neutrophils, 
macrophages, dendritic cells, and Helper T cells, Th1 and Th17.  Inflammation is an immune-
system mediated process that is typically activated after tissue injury or invasion of a pathogen. 
These stimuli then promote leukocytes, such as macrophages and mast cells, to release 
proinflammatory proteins and chemicals, termed mediators. Chemical messengers, known as 
cytokines, move from cell to cell and communicate with them to release more inflammatory 
signals. The most prevalent proinflammatory cytokines in RA and CD are Interleukins (IL-1, IL-
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6, IL-12, IL-17), Interferon (IFN), and Tumor Necrosis Factor (TNF). TNF is one of the most 
essential perpetrators in RA and CD progression. TNF is produced by mononuclear phagocytes 
and induces angiogenesis and adhesion molecule expression (Ticani, Andreoli, Bazzani, Bosiso, 
& Sozzani, 2007). Release of proinflammatory cytokines facilitates the dilation of blood vessels, 
which allows more leukocytes, such as neutrophils and macrophages, to relocate to the infected-
area via chemotaxis. The extravasation of leukocytes is mediated by endothelial cells’ selectins 
and integrins. Once these leukocytes reach the target area, they release more cytokines, granules, 
enzymes, such as proteinase, and ROS/RNS that induce tissue damage (Medzhitov, 2008). The 
entire inflammatory process causes redness, swelling, and heat release. Resolution of 
inflammation occurs when the mediators are turned off or broken down by the body, in a cleanup 
process. This cleanup process involves the cessation of white blood cell recruitment and the 
removal of white blood cells from the infected area. Macrophages, especially the M2-Like ones, 
participate in the clean up by removing dead leukocytes and releasing pro-resolving mediators. 
Pro-resolving mediators include resolvin E1, Lipoxin A4, TGF-β, IL-9, adenosine, and pro-
apoptotic factors (TRAIL, FasL) (Schett & Neurath, 2018). Resolution of inflammation protects 
against further tissue damage. RA and CD are both characterized by the non-resolution of 
inflammation. When inflammation is not shut off, leukocytes continue to release 
proinflammatory meditators that lead to chronic tissue damage, granuloma formation, and 
increasing severity of disease symptoms. 
Environmental Factors Linked to RA and CD Susceptibility 
Smoking 
 RA and CD share similar genetic and environmental susceptibility factors. Identifying 
these susceptibility factors could help to shift how researchers and doctors tackle these immune-
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mediated diseases. More importantly, greater insight into the factors that increase one’s 
susceptibility to these diseases could initiate a disease prevention initiative. One of the most 
well-studied environmental risk factors for RA and CD is smoking. Studies with monozygotic 
twins, in which one smoked and the other did not, demonstrated that the smokers developed RA 
in 12/13 cases (Klareskog et al., 2009). Smoking acts as a risk factor for the rheumatoid factor-
positive and ACPA-positive RA subsets (Klareskog et al., 2009). The reason for this lies in the 
role of the PAD enzyme in exacerbating the autoimmune reactions in RA. When cigarette 
particles enter the lungs, resident macrophages are activated and induce the death of lung cells. 
This promotes the activity of the PAD enzyme. The resulting citrullinated proteins then bind to 
MHC on immune cells and promote the synthesis of ACPAs (Klareskog et al., 2009). These 
antibodies attack the body’s own cells, promote inflammation, and increase the severity of RA.  
Similarly, smoking increases the risk of developing CD. This association has been linked 
to a prevalent genetic susceptibility factor in CD. A prominent mutation in Paneth cells 
(ATG16L1T300A) is triggered by tobacco smoke (Liu et al., 2018). This mutation leads to 
Paneth cell dysfunction, which is characteristic of CD. This defect impairs autophagy and the 
antimicrobial granule production (Baumgart & Sandborn, 2012). Furthermore, prenatal and 
childhood exposure to second-hand smoking increases one’s chances of developing CD (Dutta & 
Chacko, 2016). These findings illustrate that both RA and CD share smoking as an 
environmental risk that could be controlled or ceased to prevent or delay the onset of these two 
diseases.  
Oral-Gut Dysbiosis 
 Another environmental risk factor shared by RA and CD is the irregularity of the oral-gut 
microbiome. The oral-gut microbiome, a community of bacteria that reside in the gastrointestinal 
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tract, mouth, skin, and urinary tract, has been shown to play an increasingly prominent role in the 
development of CD and RA. Its association to CD is not as surprising considering that CD’s 
etiology is in the intestinal tract; it is much more interesting to note the recent associations 
between RA and the gut microbiome. Dysbiotic links shared between the two diseases highlight 
more inflammatory causes that could be intervened as possible treatments.  
         The gut microbiome-inflammation link has both environmental and genetic components. 
The gut microbiome irregularity, termed dysbiosis, is present in CD and RA patients. Dysbiosis 
can be caused by various factors, such as diet, drug use, antibiotic use, and aging (Du Teil Espina 
et al., 2018). However, recent research recognizes that dysbiosis may be a symptom and cause of 
RA and CD. Dysbiosis involves an overall decrease in the diversity of gut bacteria (Hedin, Van 
der Gast, Stagg, Lindsay, & Whelan, 2017), a decrease in Firmicutes (i.e. Clostridium, 
Faecalibacterium prausnitzii), and an increase in the Proteobacteria phylum (i.e. Family: 
Enterobacteriaceae such as Escherichia coli) (Boyapati et al., 2015; NIH, 2017; Hedin et al., 
2017).  Interestingly, this decrease in bacterial diversity has also been linked to smoking, 
colorectal cancer, and obesity (Hedin et al., 2017). Bacteria such as E. coli  have been shown to 
activate inflammation after interaction with epithelial cells. E. coli then induce macrophages to 
release more proinflammatory chemical messengers, such as TNF (Boyapati et al., 2015). These 
findings were further solidified after a University of Pennsylvania study concluded that the 
Proteobacteria phylum also initiated intestinal inflammation in mice (Ni et al., 2017). This means 
that Proteobacteria, which are already in high levels in the intestine of CD patients, induce 
intestinal inflammation and continue to promote it. Another study analyzed the gut microbiota of 
CD-afflicted and non-afflicted siblings. This study found that both siblings had similar gut 
microbiota compositions and both displayed dysbiotic characteristics (Hedin et al., 2017). 
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Therefore, dysbiosis is not merely a consequence of inflammatory conditions; it is also an 
instigator in CD pathogenesis and a risk factor. It’s role as a susceptibility factor in CD 
development could be a possible target for CD onset prevention. 
Dr. Gary D. Wu and his team at the University of Pennsylvania investigated the role of 
nitrogen metabolism in dysbiosis. The researchers found that there was an increase in nitrogen 
metabolism and an increase in amino acid levels in the stools of CD patients; increased nitrogen 
metabolism is due to certain bacteria producing the urease enzyme, which makes ammonia to 
sustain growth (Ni et al., 2017; NIH, 2017). A positive correlation was found between urease 
presence and dysbiotic activity. If there is more urease, then more amino acid/amino acid 
derivatives will be produced. The study found that higher amino acid levels in fecal samples 
correlated to more intestinal inflammation and higher levels of Proteobacteria. Interestingly, 
when the researchers used a urease-negative E. coli strain, no signs of dysbiosis were present (Ni 
et al., 2017). The negative results observed here indicates that dysbiosis development may 
depend on the presence of bacterial urease. Such findings need to be observed in humans in order 
to determine the role urease may play in causing gut dysbiosis, and therefore CD- intestinal 
inflammation. 
The health of the oral-gut microbiome in RA patients provides clues into the 
development of RA. Oral dysbiosis in RA patients may include increases in bacteria such as 
Lactobacillus salivarus, Prevotella, and Cryptobacterium curtum. Periodontitis, chronic 
inflammation of the tissue surrounding teeth, has been linked to RA since 1918 (Du Teil Espina 
et al., 2018). Patients with periodontitis are twice as likely to develop RA. The reason for this 
lies in a bacterium that causes periodontitis, Porphyromonas gingivalis. P. gingivalis can travel 
from the oral cavity, through the bloodstream, and into the synovial fluid surrounding the joints. 
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P. gingivalis has an enzyme known as PPAD, that is similar in function to the PAD enzyme that 
is essential in the development of RA auto-antibodies (ACPAs). This example of molecular 
mimicry allows for a human’s antibodies to recognize the bacterial citrullinated proteins, thereby 
inducing an immune response like that of RA ((Du Teil Espina et al., 2018). This response 
aggravated the symptoms of RA (i.e. increased joint damage) by allowing the mobilization of 
more immune cells, such as Th17, and increasing the production of proinflammatory cytokines 
(IL-17) and autoantibodies (Du Teil Espina et al., 2018). P. gingivalis may further exacerbate the 
inflammatory symptoms of RA by targeting neutrophils. Neutrophils in RA synovium exhibit 
amplified Neutrophil Extracellular Traps (NETs) release, which is accompanied by the release of 
citrullinated proteins, the same proteins that are recognized and targeted for destruction by the 
ACPA antibodies. This continues the inflammatory and tissue-destructive cycle present in RA. 
These results demonstrate that oral bacteria exert influence beyond the oral cavity. In the case of 
RA, oral bacteria may contribute to gut dysbiosis. Oral bacteria’s ability to travel to and live in 
the gut, alter the microbiome, and induce chronic inflammation needs to be curbed for patients 
with dysbiosis and RA. 
 Genetic Factors Linked to RA and CD Susceptibility 
         RA and CD share genetic factors that play a role in the development and pathogenesis of 
both diseases. RA’s heritability is about 60%, whereas CD’s heritability ranges from 25-42% 
(Kurkó, Besenyei, Laki, Glant, Mikecz, & Szekanecz, 2013; Gordon, Trier, Moller, Andersen & 
Harbord, 2015). Genetic factors contribute to approximately 50% of the overall development of 
RA (Klareskog et al., 2009). There are approximately 30 loci implicated in RA’s development 
(Kurko et al., 2013). Likewise, CD’s etiology is based on genetic mutations in over 71 loci on 17 
chromosomes (Baumgart & Sandborn, 2012). CD’s genetic risk is further heightened by the fact 
10
Mako: NSU Undergraduate Student Journal, Vol. 2020 [], Art. 4
https://nsuworks.nova.edu/mako/vol2020/iss1/4
INTERPLAY OF RA AND CD                                                                                              10 
 
 
that monozygotic twins have an increased risk of developing CD compared to dizygotic twins 
(Baumgart & Sandborn, 2012). These results demonstrate that environmental and epigenetic 
factors are not solely responsible for RA and CD development. One of the most well-studied 
genetic factors for RA is HLA-DRB1, whereas NOD2/CARD15 is the most recognizable genetic 
factor for CD. However, there are two major genetic mutations shared by both RA and CD that 
occur in the PTPN2/22 and STAT4 genes. Understanding the underlying genetic causes of these 
two diseases is essential in taking steps toward early diagnoses. 
PTPN2/N22 
One well researched correlation between the two is the mutations in certain immune 
system regulatory genes, known as Protein Tyrosine Phosphatase Non-receptor type 2 and 22 
(PTPN2/22) genes. These genes function to regulate immune responses by coding for 
phosphatases. These phosphatases remove phosphate, from T cell receptors (TCR), Signal 
Transducers and Activators of Transcription (STAT) dimers, and BH3-only proteins (BIM) 
(Sharp, Beg, & Naser, 2018). BIM is a pro-apoptotic protein that is involved in the intrinsic 
programmed cell death pathway (Gogada et al., 2012). The intrinsic apoptosis pathway is in the 
mitochondria of cells and allows for the release of caspase proteins. The STAT1 gene codes for a 
STAT protein that plays a role in JAK/STAT cytokine receptor signaling (NCBI, 2019). In this 
pathway, a cytokine binds to receptors on the surface of a target cell. These receptors dimerize 
and bring two Janus Kinase (JAK) molecules together for activation. The tails of the receptors 
act as binding sites for STATs. Once JAK phosphorylates STAT, STAT dimerizes and changes 
shape in order to enter the nucleus of the cell. Once there, various STATs will promote cell 
proliferation, differentiation, and growth. The TCR binds to presented antigens and is then 
activated to stimulate various signal transduction pathways. Activation of T cells have vastly 
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different effects depending on the type of T cell. The lack of phosphates on the TCR and BIM, 
inactivate them (Sharp et al., 2018).  Dephosphorylation of STAT prevents it from dimerizing 
and entering the nucleus. As such, this negatively regulates chemokine production (Sharp et al., 
2018). Mutations of the PTPN2/22 genes could interfere with the regulation of the immune 
response. Without proper dephosphorylation, TCRs, BIMs, and STATs will be unrestrictedly 
active. In RA and CD, this would stimulate T cells to constantly secrete proinflammatory 
cytokines and hinder the ability of epithelial cells in the joints and intestine to induce leukocyte 
cell death. This would lead to a toxic cycle of activated leukocytes promoting inflammation. 
         A study performed by Dr. Saleh Naser and his team at the University of Central Florida 
sought to determine which mutations on the PTPN2/22 genes were responsible for the 
hyperproliferation of T cells in RA. The study found that the single nucleotide polymorphism 
(SNP) rs478582 in PTPN2 and rs2476601 in PTN22 were significant in the development of RA. 
Dr. Naser and his team concluded that patients with both mutations had 6.5-fold more risk of 
getting RA than the control subjects. The PTPN22 rs2476601 SNP (location: 1p12) was also 
identified as a susceptibility locus for CD. Different SNPs in PTPN2 such as rs1893217, 
rs740495, and rs1736020, were identified in CD (Baumgart & Sandborn, 2012). The rs2476601 
and rs478582 SNPs increased T cell proliferation and the expression of Interferon-y (IFN-y). 
Greater T cell proliferation as mentioned earlier means that there was a lack of regulation by 
PTPN2/N22. This would further promote the inflammatory cycle seen in RA. Interestingly, not 
only were the mutations that inhibited PTPN2/22 prevalent in RA subjects, but overall there was 
less PTPN2/22 mRNA expression (Sharp et al., 2018). This indicates that mutations and overall 
reduced expression of these two regulatory genes exacerbate the disease process. It does so by 
allowing the TCR to be responsive to antigen presentation by an antigen-presenting cell that was 
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stimulated by proinflammatory cytokines, such as TNFα and IL-1. Activation of the TCR then 
initiates the NF-kB signaling pathway. This pathway ends when the NF-kB transcription factor 
goes to the nucleus and stimulates the expression of cytokines and chemokines. These cytokines 
bind to epithelial cells, stimulate the JAK/STAT pathway to produce more chemokines, and 
inhibit apoptosis. Both RA and CD feature an imbalance between T effector cells and regulatory 
T cells (Treg). As such, Th cells, particularly Th17, are overactive, whereas Treg cells are not. 
When Th17 cells are continually activated and present in large amount, they induce greater tissue 
damage by producing more IL-17 and 1L-22. Since both RA and CD are heavily T cell mediated, 
the consequences of PTPN2/22 dysfunction and its role in the T effector and Treg cell imbalance 
need to be further investigated.  
STAT4 
         Another genetic susceptibility factor shared by RA and CD is STAT4. As mentioned 
above, STAT encompasses a group of transcription factor proteins that play a role in signal 
transduction pathways. STAT4 is located within dendritic cells and macrophages (Gu et al., 
2015). STAT4 is responsible for promoting the differentiation of T cells into helper T cells, 
particularly Th1 and Th17, the activation of monocytes, and the production of IFN-y, IL-12, and 
IL-23 (Glas et al., 2010). This transcription factor plays a role in the pathogenesis of both RA 
and CD. In CD, STAT4 has been shown to be constitutively activated. One genotypic study 
performed by Dr. Stephan Brand and his team from the University of Munich, found that the 
patients homozygous for STAT4 SNP rs7574865 presented with earlier onset of CD symptoms 
and more frequent disease compared to the wildtype and heterozygous genotypes (Glas et al., 
2010). The association between RA and STAT4 has been studied for well over a decade. 
However, there are some discrepancies in the overall conclusions of these case-control studies; 
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the main discrepancy lies between ethnic groups. Some studies have found no significant 
correlation between STAT4 mutations and RA, whereas others have when using a different 
ethnic group as the test and control subjects. For example, one case study found that the minor T 
allele of the STAT4 SNP rs7574865 was not significantly associated with Syrian RA patients 
(Tarakji, Habbal, & Monem, 2018). On the other hand, a meta-analysis conducted by a team of 
researchers in China, demonstrated that ethnicity and genotype play a role in the degree of 
susceptibility conferred by the STAT4 SNP rs7574865 gene. According to this analysis, the TT, 
GT +TT, and T allele genotypes were significantly associated with RA within the European, 
Asian, African, and Latin American ethnic groups (Gu et al., 2015). These associations were 
independent of whether the subject had Rheumatoid Factor-positive or negative RA. While there 
is still not a conclusive theory of the association between RA and the STAT4 SNP, the status of 
STAT4 in RA-affected joints is conclusive; STAT4 over-expression in the synovium of RA 
patients is linked to the rs7574865 mutation (Gu et al., 2015).  Nonetheless, this degree of 
uncertainty concerning STAT4 and RA’s association highlights a major issue when testing for 
susceptibility genes: patients diagnosed with the same disease may have varying genetic causes. 
Ethnicity may be an important environmental factor that could hint at varying degrees of 
susceptibility to diseases. Therefore, it is imperative that the healthcare paradigm move towards 
individual screenings, and treatments for people who present similar symptoms of a disease.  
Current Treatments for RA and CD 
         RA and CD share more than the same susceptibility factors; they share much of the same 
treatments. There are no cures for RA and CD; as such, treatment is geared towards reducing or 
resolving symptoms. The current treatments for RA and CD range from synthetic drugs to 
biologic agents; nonetheless the focus of treatment is mainly on suppressing inflammation, 
14
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reducing disease activity and potentially entering a remission state. This stems from the treat-to-
target approach utilized in autoimmune disease intervention.  
The main classes of drugs prescribed are disease-modifying antirheumatic/anti-
inflammatory drugs (DMARDs/DMAIDs), glucocorticoids, and nonsteroidal anti-inflammatory 
drugs (NSAIDs).  The main issues with common RA and CD drugs are the risk of aggravating 
comorbidities, high costs, and side effects. NSAIDs such as aspirin and acetaminophen, reduce 
swelling but are not as commonly prescribed when treating CD because of their tendency to 
irritate the intestinal lining (Crohn’s and Colitis Foundation, 2005).  NSAID side effects also 
include osteoporosis, hypertension, and ulceration in RA patients (Sharp et al., 2018). 
Glucocorticoids, such as Prednisone, mimic the effects of cortisol and suppress the immune 
system. However, they are not for long-term use because of the higher risk of infections and 
cardiovascular complications compared to other treatment types (Burmester & Pope, 2017). 
DMARDs and DMAIDs are used to intervene the damage to the joints and intestinal mucosa. 
The common DMARDs are listed in Table 1 below. The most commonly prescribed synthetic 
DMARD is Methotrexate. Methotrexate is often used as the initial monotherapeutic drug when 
starting RA treatment.  Conventional DMARDS, such as Methotrexate, can lead to fatigue, liver 
damage, nausea, cytopenia, intolerance by the gastrointestinal tract, and increased risk of 
infections (Burmester & Pope, 2017).  Furthermore, Methotrexate is not advised for women who 
intend to bear children and for those with liver conditions (Baumgart & Sandborn, 2012). 
However, combination therapy of Methotrexate with a biologic agent can be more effective than 
monotherapy (Burmester & Pope, 2017).  
Biologic agents are more targeted; however, they do increase the risk of acquiring 
infections, higher cholesterol, psoriasis and congestive heart failure (Burmester & Pope, 2017). 
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Biologics are typically delivered via injections. Specific biologic drugs target different chemicals 
and proteins in the body, and thereby lead to unique adverse events. For example, drugs that 
inhibit JAK, such as Tofacitinib, could promote gastrointestinal side effects and lymphopenia. 
The most commonly used biologic in RA and CD treatment is anti-TNF (Sharp et al., 2018). The 
side effects of anti-TNF drugs include increased risk of tuberculosis, herpes zoster infection, 
psoriasis, hepatotoxicity, and lymphomas (Burmester & Pope, 2017; Park & Jeen, 2018). 
Another complication with the use of biologic therapies is the threat of anti-drug antibody 
formation. The body may recognize a drug-based monoclonal antibody as a foreign threat and 
seek to eliminate it. The drug would be treated as a foreign antigen and be presented to T and B 
cells. This would then lead to the differentiation of plasma cells which will secrete antibodies 
against the drug. These antibodies neutralize or lower the half-life of the drug (Fiehn, 2016).  
This was seen in popular anti-TNF biologics, such as Infliximab and Adalimumab (Fiehn, 2016). 
Methotrexate used in conjunction with a biologic agent, has been shown to decrease the 
production of anti-drug antibodies and thereby increase the survival of the drug in the body. This 
demonstrated that combination therapy with methotrexate and a biologic is more effective. This 
treatment approach helps to lower inflammation, while also reducing tissue damage (Klareskog 
et al., 2009). Another significant benefit of anti-TNF and methotrexate combination therapy is 
the decreased threat to the cardiovascular system (Fiehn, 2016).  Combination therapy, while the 
most efficient, is still only effective in half of CD treatment cases (Boyapati et al., 2015). The 
complications associated with synthetic drugs and biologic agents often lead to patients 
constantly changing drugs or changing doses. Ten years after diagnosis with CD, approximately 
47% of patients need surgery, but still relapse afterwards (Bressler et al., 2015). With RA drug 
therapy, 40% of patients still become disabled in ten years (Chauhan & Al-Dhajir, 2018). More 
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effective treatment options need to be developed in order to resolve chronic inflammation and 
achieve long-lasting remission. 
Table 1. Common DMARDs Used to Treat RA and CD 
Drug Formula Purpose 
Methotrexate Folate antagonist Inhibits adenosine 
metabolism  
Infliximab IgG monoclonal antibody Anti-TNF 
Etanercept TNF receptor with IgG1’s FC 
domain 
Anti-TNF 
Adalimumab Human IgG monoclonal 
antibody 
Anti-TNF 
Anakinra IL-1 receptor antagonist Binds to IL-1 receptor to 
prevent IL-1 from binding 
to its receptor  
Tofacitinib (Xeljanz)& 
Baricitinib 
Janus Kinase Inhibitor Binds to JAK and stops 
activation of the 
JAK/STAT pathway 
Tocilizumab Monoclonal antibody Anti-IL6 receptor 
Rituximab Monoclonal antibody Anti-CD20-deactivates B 
cells 
Abatacept CTLA4 and Fc region of IgG Blocks the CD28-B7 
interaction by binding to 
B7 ligand on APCs 
  
RA and CD Disease Prevention and Intervention Proposals 
 The previous discussion about the most common treatments for RA and CD has made it 
clear that new treatment avenues need to be taken. Treating just the symptoms of RA and CD is 
not enough. Remission for both diseases could be achieved if the diseases are treated early in 
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order to stop major tissue damage (Hanauer, 2017). Therefore, better preventive steps should be 
implemented. Since RA and CD have relatively high heritability and genetic causal factors, pre-
disease genetic screening is essential in identifying one’s degree of susceptibility to these 
diseases. Since RA typically affects older adults, with typical disease onset during the range of 
30 to 60 years old, genetic screenings should be conducted at the age of 30 and every ten years 
afterwards. CD’s onset targets a younger population ranging from 15 to 35 years old. As such, 
genetic screenings should take place after puberty onset and every ten years afterwards.  
Identification of the PTPN2/22 and STAT4 mutations early could allow for proper steps to be 
taken to delay onset of the two diseases. Additionally, the oral and gut microbiota of patients 
with moderate to severe RA and CD should be analyzed. Proper analysis could identify dysbiosis 
as a factor in disease progression. Therefore, appropriate steps, such as the use of probiotics, can 
be taken to correct this measure. Furthermore, a disease prevention initiative could be undertaken 
in primary care clinics to address the importance of oral health and cessation of smoking. 
Patients need to be informed of the effects of P. gingivalis on oral health and inflammation, so 
that they may take steps in their daily routines to help lower the severity of RA symptoms. 
Furthermore, all individuals whom are genetically susceptible to RA and/or CD should be 
informed of the risks smoking carries, in order to eventually develop a plan to limit or quit the 
habit to lessen the risk of developing these diseases.  
 Treatments to Limit Leukocyte Extravasation 
Currently, the most common biologic treatment for both RA and CD is anti-TNF drugs. 
These drugs neutralize TNF cytokines, which does play an essential role in perpetuating chronic 
inflammation. However, TNF is just a mediator of inflammation. As mentioned above, anti-drug 
antibody formation and increased risks of infections are major risks associated with Anti-TNF 
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treatment. Anti-TNF treatment can lead to primary non-response in 10-30% of patients, and loss 
of response in 23-46% of patients (Park & Jeen, 2018). Nonetheless, immunotherapy can be a 
highly selective and potent treatment when used properly. Cytokines do not remain in one 
location; chemotaxis allows distant leukocytes to respond to the cytokine signals and translocate. 
Leukocytes respond to these chemical signals and release more proinflammatory factors.  As 
such, greater emphasis needs to be on targeting leukocytes themselves. Limiting the 
extravasation of neutrophils via use of anti-integrins may be the key. Integrins are heterodimeric 
receptors on the surface of leukocytes, which interact with adhesion molecules on endothelial 
cells. Targeting integrin would limit the influx of leukocytes into inflamed tissues. A possible 
target for both diseases would be α4β1, an integrin molecule expressed on many leukocytes. One 
anti-integrin drug, Natalizumab (anti-α4 subunit), became a premier treatment for CD. However, 
the drug unintentionally reached the central nervous system and lead to increased risk of brain 
infections. This dilemma mimics a common trend with current biologic agents: these agents tend 
to have systemic effects, rather than local effects. Systemic immunosuppression leads to adverse 
side effects and increased risks of infections. Therefore, more precisely targeted immunotherapy 
options must be pursued. For CD, specifically, α4β7 would be apt target because it is found on 
GI lymphocytes (Park & Jeen, 2018).  As such, Vedolizymab, an IgG antibody against α4β7 
integrin that is specific to the intestine, is a better option for CD patients. Clinical trials have 
shown that Vedolizymab initiated mucosal healing, did not affect brain immunity, and only had a 
4% chance of developing anti-drug antibodies (Park & Jeen, 2018). Its side effects include 
headache, nausea and nasopharyngitis, which are must less severe than Anti-TNF inhibitor side 
effects. A similar RA treatment targeting integrins specific to the synovial membrane, such as 
α5β1 integrin which recognizes fibronectin, α1β1, α10β1, and α11β1 which recognize collagen, 
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could be successful in limiting lymphocyte extravasation (Lowin & Straub, 2011). Intercepting 
extravasation could be extremely beneficial to patients suffering from numerous inflammatory 
conditions as it stops the cycle of cytokine-lead inflammation. Further research on the effects of 
tissue-specific anti-integrin therapies need to be conducted to gauge the efficacy and safety of 
such treatments.  
Another treatment aimed at limiting extravasation is E6011. E6011 is currently 
undergoing clinical trials for CD. E6011 is a monoclonal IgG antibody that targets fractalkine 
(FKN), which is a CX3C chemokine that enables integrin-independent and dependent leukocyte 
extravasation (Tanaka et al., 2017). E6011 has already shown promising results for RA patients; 
E6011 reduces inflammation and leads to decreased swelling and tenderness around joints 
(Tanaka et al., 2017). The adverse effects of E6011 are much less severe than other biologic 
agents, thereby making it a promising immunotherapy.  
The Use of IL-9 and ILC2 in Resolving Inflammation 
 RA and CD are characterized by the non- resolution of inflammation. Current biologic 
treatments tend to target proinflammatory cytokines. However, there are pro-resolving cytokines 
that could be the future of cytokine-targeted therapy. One promising avenue is the use of Type 2 
Innate Lymphoid Cells (ILC2s). ILC2s produce IL-9, IL-4, and IL-13, activate Treg’s, and trigger 
the expression of the M2 macrophage phenotype (Schett & Neurath, 2018). IL-9 and ILC2 levels 
are lowered in patients with RA (Rauber et al., 2017). IL9 overexpression has been shown to 
accelerate the resolution of RA, resolve joint swelling, reduce synovitis, and lower tissue damage 
and bone erosions by activating ILC2s in mice models (Rauber et al., 2017). IL-9’s anti-
inflammatory effects could also be useful in reducing granuloma and mucosal damage in CD. 
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Promoting ILC2 and IL-9 expression could possibly the key to resolving inflammation and 
inducing tissue repair in chronic inflammatory conditions. 
Restoring Eubiosis via Probiotics 
 This literature review delved into the association between dysbiosis and RA and CD. 
Dysbiosis seems to be both a causal factor and an effect of the two diseases. As such, proper 
preventative and interventionist measures could be taken to reduce the risk of getting these 
diseases in genetically predisposed individuals or to decrease the chronic inflammation in 
already affected patients. One possible treatment avenue is the use of probiotics to restore 
eubiosis. Prevotella histicola, Lactobacillus casei, and Lactobacillus paracasei have been shown 
to be possible routes to eubiosis. P. histicola ameliorates arthritis in mice; L. casei uses 
lactoceptin, a protease, to reduce the amount of proinflammatory cytokines in RA patients (Du 
Teil Espina et al., 2018). L. casei is already a marketable probiotic; it is found in certain 
probiotic supplements, cheeses and yogurts. One study found that Lactobacillus rhamnosus 
stopped the formation and release of NETs (Du Teil Espina et al., 2018). Limiting NETosis 
would decrease the amount of ACPAs, as mentioned earlier in this paper. Another promising 
probiotic is commensal bacteria, Faecalibacterium prausnitzii, which are decreased in dysbiotic 
individuals.  F. prausnitzii has been shown to be anti-inflammatory by decreasing the IL-8 
levels, increase pro-resolving IL-10 levels (Martin et al., 2017). The brand, OMNI-Biotic created 
a supplement which contains fructo-oligosaccharides and galacto-oligosaccharides to promote 
the proliferation of F. prausnitzii. Therefore, the bacterial growth is being promoted indirectly. 
In the future, more direct administration of the probiotic could be a more potent therapy. The use 
of probiotic therapy may be the key to restoring eubiosis, which might then limit the symptoms 
of chronic inflammation. Further testing needs to be conducted with human subjects in order to 
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measure the effects of probiotic treatment on dysbiosis and inflammation. Dysbiosis may also be 
countered by more invasive measures, such as a fecal microbial transplantation (FMT). Targeting 
P. gingivitis is another probable method. P. gingivitis exacerbates inflammation due to molecular 
mimicry. One study showed that an antibody against the fibrillin protein made by P. gingivitis 
helps to alleviate periodontitis and RA. For patients with extreme dysbiosis, the use of antibiotics 
may be helpful. The study conducted by Dr, Wu and his team at the University of Pennsylvania 
demonstrated that a combination therapy of vancomycin, neomycin, and PEG altered the 
microbiota of subjects favorably (Ni et al., 2018). However, the use of antibiotics must be 
cautioned due to their ability to further decrease the diversity of the gut microbiota. Therefore, 
probiotics could be the least aggressive option in restoring eubiosis.  
Concluding Remarks 
 RA and CD share genetic and environmental factors that lead to disease onset and 
progression. The current treatments for RA and CD are aimed towards inflammation suppression 
and have adverse side effects that limit long term use of the same medication and dosage. 
Therefore, the use of anti-integrins and pro-resolving cytokines could help to resolve 
inflammation, while the use of probiotics could naturally restore gut eubiosis. Overall, health 
promotion and disease prevention initiatives targeted towards smoking and oral/gut health could 
be of great value in delaying the onset of these diseases in genetically predisposed individuals.  
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Appendix A 
Table 2. Abbreviations 
Abbreviation Definition 
ACPA Antibodies against citrullinated protein antigens 
BIM BH3-only protein 
CD Crohn’s Disease 
DMAID Disease modifying anti-inflammatory drug 
DMARD Disease modifying anti-rheumatic drug 
FasL Fas Ligand 
HLA-DRB1 Human leukocyte antigen DRB1gene 
IFN Interferon 
Ig Immunoglobulin (antibody) 
IL Interleukin 
ILC2 Type 2 innate lymphoid cell 
JAK Janus kinase 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
NET Neutrophil extracellular trap 
NF-κB Nuclear factor kappa light chain enhancer of 
activated B cells 
NOD Nucleotide binding oligomerization domain 
containing protein 
NSAID Non-steroidal anti-inflammatory drug 
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PAD Peptidylarginine deiminase 
PTPN2/22 Protein tyrosine phosphatase non-receptor type 2 
and 22 
RA Rheumatoid Arthritis 
ROS/RNS Reactive oxygen/nitrogen species 
SNP Single nucleotide polymorphism 
STAT Signal transducer and activator of transcription 
TCR T cell receptor 
Th Helper T cell 
TLR Toll like receptors 
TNF Tumor necrosis factor 
TRAIL TNF-Related Apoptosis Inducing Ligand 
Treg Regulatory T cell 
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